Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MARKER THERAPEUTICS, INC. (MRKR : NSDQ)
 
 • Company Description   
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.80 Daily Weekly Monthly
20 Day Moving Average: 86,836 shares
Shares Outstanding: 11.31 (millions)
Market Capitalization: $20.37 (millions)
Beta: 1.43
52 Week High: $5.99
52 Week Low: $0.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 6.51% 2.52%
12 Week 56.52% 31.66%
Year To Date -42.12% -45.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2450 Holcombe Blvd Suite BCM-A
-
Houston,TX 77021
USA		 ph: 713-400-6400
fax: -		 investor.relations@markertherapeutics.com http://www.markertherapeutics.com
 
 • General Corporate Information   
Officers
Juan Vera - President; Chief Executive Officer and Treasurer
N. David Eansor - Chairman
Katharine Knobil - Director
Steve Elms - Director
John Wilson - Director

Peer Information
MARKER THERAPEUTICS, INC. (GSAC)
MARKER THERAPEUTICS, INC. (CASI)
MARKER THERAPEUTICS, INC. (ALCD.)
MARKER THERAPEUTICS, INC. (OMNN)
MARKER THERAPEUTICS, INC. (CGPI.)
MARKER THERAPEUTICS, INC. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 57055L206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 11.31
Most Recent Split Date: 1.00 (0.10:1)
Beta: 1.43
Market Capitalization: $20.37 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.41
Price/Cash Flow: -
Price / Sales: 3.58
EPS Growth
vs. Year Ago Period: -48.15%
vs. Previous Quarter: 4.76%
Sales Growth
vs. Year Ago Period: -71.95%
vs. Previous Quarter: -84.50%
ROE
06/30/25 - -
03/31/25 - -101.87
12/31/24 - -90.38
ROA
06/30/25 - -
03/31/25 - -83.02
12/31/24 - -73.13
Current Ratio
06/30/25 - -
03/31/25 - 6.79
12/31/24 - 6.36
Quick Ratio
06/30/25 - -
03/31/25 - 6.79
12/31/24 - 6.36
Operating Margin
06/30/25 - -
03/31/25 - -224.46
12/31/24 - -162.83
Net Margin
06/30/25 - -
03/31/25 - -224.46
12/31/24 - -162.83
Pre-Tax Margin
06/30/25 - -
03/31/25 - -223.56
12/31/24 - -162.05
Book Value
06/30/25 - -
03/31/25 - 1.28
12/31/24 - 1.73
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©